The Supreme Court held (2018du47714) that raw pharmaceutical products provided free or charge under a purchase agreement were not “free of charge imports” as defined in Article 17(1) of the Enforcement Decree of the Customs Act, and therefore their customs value could be determined under Article 30 of the Customs Act.
Source: KPMG
